Associated and predictive factors of depressive symptoms in patients with Parkinson’s disease

Journal of Neurology

Volumn 263, Issue 6, 2016, Pages 1215-1225

  Zhu, Kangdi ^a   van Hilten, Jacobus J ^a   Marinus, Johan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Depression; Parkinson s disease; Prediction; Risk factors

Indexed keywords

COMPLICATION; CROSS-SECTIONAL STUDY; DEPRESSION; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; PARKINSON DISEASE; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; SURVIVAL ANALYSIS;

CROSS-SECTIONAL STUDIES; DEPRESSION; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; PARKINSON DISEASE; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84964545897     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8130-3     Document Type: Article

References (45)

1. Cummings JL (1992) Depression and Parkinson’s disease: a review. Am J Psychiatry 149(4):443–454
2. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23(2):183–189
3. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69(3):308–312
4. Hoogendijk WJ, Sommer IE, Tissingh G, Deeg DJ, Wolters EC (1998) Depression in Parkinson’s disease. The impact of symptom overlap on prevalence. Psychosomatics 39(5):416–421
5. McDonald WM, Richard IH, DeLong MR (2003) Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry 54(3):363–375
6. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB (2003) Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol 16(3):178–183
7. Rojo A, Aguilar M, Garolera MT et al (2003) Depression in Parkinson’s disease: clinical correlates and outcome. Parkinsonism Relat Disord 10(1):23–28
8. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL (1997) Risk factors for depression in Parkinson disease. Arch Neurol 54(5):625–630
9. van der Hoek TC, Bus BA, Matui P, van der Marck MA, Esselink RA, Tendolkar I (2011) Prevalence of depression in Parkinson’s disease: effects of disease stage, motor subtype and gender. J Neurol Sci 310(1–2):220–224
10. Jasinska-Myga B, Putzke JD, Wider C, Wszolek ZK, Uitti RJ (2010) Depression in Parkinson’s disease. Can J Neurol Sci 37(1):61–66
11. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR (2011) Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol 18(3):448–453
12. Leentjens AF, Lousberg R, Verhey FR (2002) Markers for depression in Parkinson’s disease. Acta Psychiatr Scand 106(3):196–201
13. Schrag A, Jahanshahi M, Quinn NP (2001) What contributes to depression in Parkinson’s disease? Psychol Med 31(1):65–73
14. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990) Depression in Parkinson’s disease. J Nerv Ment Dis 178(1):27–31
15. Kuopio AM, Marttila RJ, Helenius H et al (2000) The quality of life in Parkinson’s disease. Mov Disord 15(2):216–223
16. Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ (2008) Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord 23(1):35–41
17. Dissanayaka NN, Sellbach A, Silburn PA, O’Sullivan JD, Marsh R, Mellick GD (2011) Factors associated with depression in Parkinson’s disease. J Affect Disord 132(1–2):82–88
18. Kostic VS, Filipovic SR, Lecic D et al (1994) Effect of age at onset on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 57(10):1265–1267
19. Berrios GE, Campbell C, Politynska BE (1995) Autonomic failure, depression and anxiety in Parkinson’s disease. Br J Psychiatry 166(6):789–792
20. Aarsland D, Larsen JP, Cummins JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56(5):595–601
21. van der Heeden JF, Marinus J, Martinez-Martin P et al (2014) Importance of nondopaminergic features in evaluating disease severity of Parkinson disease. Neurology 82(5):412–418
22. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ (2007) Patient-reported autonomic symptoms in Parkinson disease. Neurology 69(4):333–341
23. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752
24. Esselink RA, de Bie RM, de Haan RJ et al (2004) Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 62(2):201–207
25. Hoehn MM, Yahr MD (2001) Parkinsonism: onset, progression, and mortality. 1967. Neurology 57(10 Suppl 3):S11–S26
26. Marinus J, Visser M, Stiggelbout AM et al (2004) A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatr 75(3):388–396
27. Verbaan D, Marinus J, Visser M et al (2007) Cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 78(11):1182–1187
28. Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22(15):2221–2228
29. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19(11):1306–1312
30. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM (2003) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26(8):1049–1054
31. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:53–63
32. Marinus J, van Hilten JJ (2015) The significance of motor (a)symmetry in Parkinson’s disease. Mov Disord 30(3):379–385
33. Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ (2006) Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease. Mov Disord 21(5):668–672
34. Lydiard RB (1991) Coexisting depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 52(Suppl 6):48–54
35. Burn DJ (2002) Depression in Parkinson’s disease. Eur J Neurol 9 (Suppl 3):44–54
36. Meyer PM, Strecker K, Kendziorra K et al (2009) Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66(8):866–877
37. van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ (2009) Patterns of motor and non-motor features in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80(8):846–850
38. Calabresi P, Mercuri NB, Di Filippo M (2009) Synaptic plasticity, dopamine and Parkinson’s disease: one step ahead. Brain 132(Pt 2):285–287
39. Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67(6):715–725
40. Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 120(2):131–143
41. Rascol O, Perez-Lloret S, Ferreira JJ (2015) New treatments for levodopa-induced motor complications. Mov Disord 30(11):1451–1460
42. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV, 4th edn. Washington, DC
43. Marsh GG, Markham CH (1973) Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry 36(6):925–935
44. Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9(6):573–580
45. Borah A, Mohanakumar KP (2007) Long-term l-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 27(8):985–996